급성 초조 및 공격성 치료 시장 규모, 점유율, 성장 분석 : 치료 종류별, 투여 경로별, 적응증별, 의료 제공 환경별, 환자 연령층별, 지역별 - 업계 예측(2026-2033년)

Global Acute Agitation And Aggression Treatment Market size was valued at USD 5.84 Billion in 2024 and is poised to grow from USD 6.17 Billion in 2025 to USD 9.54 Billion by 2033, growing at a CAGR of 5.6% during the forecast period (2026-2033).

The market for acute agitation and aggression treatment is poised for substantial growth fueled by the introduction of non-injectable formulations, which enhance accessibility and lessen reliance on trained personnel. The adoption of intranasal or sublingual delivery systems in hospitals has led to reduced de-escalation times, which alleviates overcrowding in emergency departments and shortens patient stays. This streamlined process yields cost savings, prompting insurers to support the incorporation of newer treatment options. Consequently, pharmaceutical companies are increasingly channeling resources into research and development. Success in trauma centers and psychiatric facilities highlights the potential for timely intervention, minimizing injuries, and enhancing staff safety, thereby driving the demand for innovative therapeutic products in this evolving market landscape.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Acute Agitation And Aggression Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Acute Agitation And Aggression Treatment Market Segments Analysis

Global acute agitation and aggression treatment market is segmented by treatment type, route of administration, indication, care setting, patient age group, distribution channel and region. Based on treatment type, the market is segmented into pharmacological treatment and non-pharmacological treatment. Based on route of administration, the market is segmented into oral, intramuscular (IM), intravenous (IV) and intranasal. Based on indication, the market is segmented into schizophrenia & psychotic disorders, bipolar disorder, dementia-related agitation, autism spectrum disorder-associated agitation, substance-induced agitation, delirium and other neuropsychiatric disorders. Based on care setting, the market is segmented into emergency departments, psychiatric hospitals & inpatient facilities, general hospitals, long-term care & nursing facilities and ambulatory & outpatient care centers. Based on patient age group, the market is segmented into pediatric, adult and geriatric. Based on distribution channel, the market is segmented into hospital pharmacies, retail pharmacies and online pharmacies. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Acute Agitation And Aggression Treatment Market

The growing global awareness of acute agitation and aggression among patients is driven by shifting demographics, heightened recognition of psychiatric emergencies, and expanded diagnostic criteria. This awareness leads to an increased demand for effective pharmacological treatments, prompting hospitals and emergency departments to bolster their therapeutic inventories. Consequently, there is a rising need for approved therapeutic agents, motivating manufacturers to invest in research, enhance manufacturing capabilities, and strengthen distribution networks. This dynamic fosters a positive feedback loop, further catalyzing market expansion and facilitating sustained growth across diverse healthcare settings and among various patient demographics.

Restraints in the Global Acute Agitation And Aggression Treatment Market

The Global Acute Agitation and Aggression Treatment market faces several constraints stemming from regulatory demands for safety and efficacy in treatment options. These requirements necessitate extensive clinical trials that assess rapid onset of action, cardiovascular impacts, and the risk of misuse, complicating the approval process and extending time to market while elevating development costs. This scenario deters smaller companies from entering the field, leading to a market predominantly occupied by a limited number of established players. Consequently, this consolidation restricts product diversity and stifles the introduction of innovative therapies, diminishing overall market dynamism and growth potential. Additionally, ongoing post-marketing surveillance obligations create continuous compliance challenges for manufacturers.

Market Trends of the Global Acute Agitation And Aggression Treatment Market

The Global Acute Agitation and Aggression Treatment market is experiencing a transformative trend characterized by the emergence of innovative formulation advancements. This shift towards next-generation oral and intranasal agents emphasizes rapid onset of action alongside improved safety profiles, which are vital for enhancing patient comfort and encouraging outpatient management. Pharmaceutical companies are increasingly utilizing novel molecular targets and advanced delivery technologies to fulfill unmet clinical needs, thereby minimizing the dependence on injectable treatments. Additionally, strategic collaborations with biotechnology innovators are fostering expansion within this therapeutic arena, bolstering adoption across emergency and psychiatric care settings on a global scale.

Table of Contents

Introduction

• Objectives of the Study
• Market Definition & Scope

Research Methodology

• Research Process
• Secondary & Primary Data Methods
• Market Size Estimation Methods

Executive Summary

• Global Market Outlook
• Key Market Highlights
• Segmental Overview
• Competition Overview

Market Dynamics & Outlook

• Macro-Economic Indicators
• Drivers & Opportunities
• Restraints & Challenges
• Supply Side Trends
• Demand Side Trends
• Porters Analysis & Impact
  • Competitive Rivalry
  • Threat of Substitute
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Key Success Factors
• Market Impacting Factors
• Top Investment Pockets
• Ecosystem Mapping
• Market Attractiveness Index 2025
• PESTEL Analysis
• Regulatory Landscape

Global Acute Agitation and Aggression Treatment Market Size by Treatment Type & CAGR (2026-2033)

• Market Overview
• Pharmacological Treatment
  • Behavioral De-escalation Techniques
  • Physical Restraint & Seclusion
  • Environmental & Supportive Interventions
• Non-Pharmacological Treatment

Global Acute Agitation and Aggression Treatment Market Size by Route of Administration & CAGR (2026-2033)

• Market Overview
• Oral
• Intramuscular (IM)
• Intravenous (IV)
• Intranasal

Global Acute Agitation and Aggression Treatment Market Size by Indication & CAGR (2026-2033)

• Market Overview
• Schizophrenia & Psychotic Disorders
• Bipolar Disorder
• Dementia-Related Agitation
• Autism Spectrum Disorder-Associated Agitation
• Substance-Induced Agitation
• Delirium
• Other Neuropsychiatric Disorders

Global Acute Agitation and Aggression Treatment Market Size by Care Setting & CAGR (2026-2033)

• Market Overview
• Emergency Departments
• Psychiatric Hospitals & Inpatient Facilities
• General Hospitals
• Long-Term Care & Nursing Facilities
• Ambulatory & Outpatient Care Centers

Global Acute Agitation and Aggression Treatment Market Size by Patient Age Group & CAGR (2026-2033)

• Market Overview
• Pediatric
• Adult
• Geriatric

Global Acute Agitation and Aggression Treatment Market Size by Distribution Channel & CAGR (2026-2033)

• Market Overview
• Hospital Pharmacies
• Retail Pharmacies
• Online Pharmacies

Global Acute Agitation and Aggression Treatment Market Size & CAGR (2026-2033)

• North America (Treatment Type, Route of Administration, Indication, Care Setting, Patient Age Group, Distribution Channel)
  • US
  • Canada
• Europe (Treatment Type, Route of Administration, Indication, Care Setting, Patient Age Group, Distribution Channel)
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific (Treatment Type, Route of Administration, Indication, Care Setting, Patient Age Group, Distribution Channel)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America (Treatment Type, Route of Administration, Indication, Care Setting, Patient Age Group, Distribution Channel)
  • Mexico
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Treatment Type, Route of Administration, Indication, Care Setting, Patient Age Group, Distribution Channel)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2025
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2025
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

• Eli Lilly and Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Otsuka Holdings Co Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• H Lundbeck A S
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson Services Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bristol-Myers Squibb Company
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioXcel Therapeutics Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Intra-Cellular Therapies Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Axsome Therapeutics Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Teva Pharmaceutical Industries Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Amneal Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• AstraZeneca plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F Hoffmann-La Roche Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alkaermes plc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Suven Life Sciences Limited
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Lee Pharma Ltd
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Impel Pharmaceuticals Inc
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendations